Name : Mrs.
ARCHANA Barcode No : 60008182
Age/Gender : 22 YRS/Female Reg. No : 00012305210018
Referred by : SHREE HOSPITAL Collected On : 05/Sep/2023 11:35 AM
Referring Centre : OPL016-SHREE HOSPITAL Received On : 05/Sep/2023 07:42 PM
Sample Type : Whole Blood EDTA Reported On : 06/May/2023 12:46PM
Report Status : Final
HAEMATOLOGY
Test Name Result Unit Biological Ref.Interval
OSCAR 1.3
Complete Blood Count (CBC)+ESR
HAEMOGLOBIN (Hb) 11.4 gm/dl 11.5-16.0
Methodology: SLS-Haemoglobin Method
TOTAL LEUKOCYTE COUNT (TLC) 8.1 th/cumm 4.0-10.0
Methodology: Fluorescence flow cytometry
DIFFERENTIAL LEUCOCYTE COUNT
POLYMORPHS 55 % 40-75
Methodology: Fluorescence flow cytometry
LYMPHOCYTES 35 % 20-40
Methodology: Fluorescence flow cytometry/Manual
EOSINOPHILS 04 % 1-6
Methodology: Fluorescence flow cytometry
MONOCYTES 06 % 2-10
Methodology: Fluorescence flow cytometry
BASOPHILS 00 % 0-1
Whole Blood EDTA Flowcytometry
ABSOLUTE NEUTROPHIL COUNT 4,455 /cumm 1600 - 8000
Methodology: Calculated
ABSOLUTE LYMPHOCYTE COUNT 2,835 /cumm 1392 - 3510
Methodology: Calculated
ABSOLUTE EOSINOPHIL COUNT 324 /cumm 40-440
Methodology: Calculated
ABSOLUTE MONOCYTE COUNT 486 /cumm 100-900
Methodology: Calculated
ABSOLUTE BASOPHIL COUNT 0 /cumm 0-100
Methodology: Calculated
RED BLOOD CELLS - RBC COUNT 4.0 millions/cmm 3.8-4.8
Methodology: DC detection method
HCT 33.2 % 35-45
Whole Blood EDTA, Calculated
MCV 82 fl 76-96
Methodology: Automated/Calculated
MCH 28.1 pg 27-33
Methodology: by Automated/Calculated
Page 1 of 10
Name : Mrs.ARCHANA Barcode No : 60008182
Age/Gender : 22 YRS/Female Reg. No : 00012305210018
Referred by : SHREE HOSPITAL Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016-SHREE HOSPITAL Received On : 21/May/2023 11:42 AM
Sample Type : Whole Blood EDTA Reported On : 21/May/2023 12:46PM
Report Status : Final
MCHC 34.3 g/dl 30-35
Methodology: Automated/Calculated
PLATELET COUNT 155 thou/µL 150-450
Methodology: DC detection method
unit
MEAN PLATELET VOLUME - MPV 11.7 fl 7.4-10.4
Methodology: Plt Histogram
RED CELL DISTRIBUTION WIDTH (RDW-CV) 14.9 % 11.5-14.5
Methodology: Automated/Calculated
Whole Blood EDTA, Flowcytometry
RED CELL DISTRIBUTION WIDTH (RDW-SD) 49.7 fl 35-56
Methodology: Automated/Calculated
Whole Blood EDTA, Flowcytometry
PCT(PLATELETCRIT) 0.2 % 0.10-0.28
Methodology: Calculated
PDW-SD 19.5 fl 9.00-17.00
Methodology: Calculated
Whole Blood EDTA, Calculated
NEUTROPHIL - LYMPHOCYTE RATION (NLR) 1.57
Calculated
LYMPHOCYTE - MONOCYTE RATIO (LMR) 5.83
Calculated
PLATELET - LYMPHOCYTE RATIO (PLR) 54.67
ESR [WESTERGREN] 20 mm/ 1 hr 0 -10
MODIFIED WESTERGREN
*** End Of Report ***
Page 2 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Whole Blood EDTA Reported On : 21/May/2023 12:44PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
HbA1c (Glycated hemoglobin)
Glycosylated Hb (HbA1c) 5.2 % 4.2-6.0
EDTA BLOOD, HPLC Assay
Average Glucose 103 mg/dl 0-125
Calculated.
INTERPRETATION
The following Hb A1c ranges may be used for interpretation of results ; however, factors such as
duration of diabetes, adherence to therapy & the age of the patient should also be considered in
assessing the degree of blood glucose control. These values are for nonpregnant individuals.
Hemoglobin A1c (%) Degree of Glucose Control
> 8 Action Suggested *
< 7 Goal **
< 6 Non - diabetic Level
* High risk of developing long term complications such as retinopathy, nephropathy & cardiopathy.
Action suggested depends on individual patient circumstances.
** Some danger of hypoglycemic reaction in Type 1 diabetics. Some glucose intolerant indivduals &
"sub - clinical" diabetics may demonstrate (elevated) HbA1c in this area.
Estimation of Mean Plasma Glucose (MPG)
Further clinical information may be derived from the HbA1c value by using it to estimate the mean
plasma glucose (MPG) level over the last 60 days.
This estimation may not be used with the less specific methods (total HbA1c & total glycated Hb) since
the correlation of the HbA1a and HbA1b fractions with long - term glucose control is very questionable.
HbA1c (%) MPG Estimate ( mg/dl).
6.0 135
7.0* 170
9.0 240
*ADA Target
Non - diabetic (Normal) Range
The weighted mean HbA1c for patients with normal fasting plasma glucose was 5.17% with the standard
deviation of 0.45%.
*** End Of Report ***
Page 3 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Serum Reported On : 21/May/2023 01:28PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
BIOCHEMISTRY
IRON PROFILE BASIC
Iron 39.3 ug/dl 37-145
Serum, FerroZine without deproteinization
TIBC* 325.2 ug/dL 250-400
Calculatedl
UIBC* 285.9 ug/dL 63 - 433
Serum, Biochemical
Transferrin Saturation * 12.08 % 15-55
Calculated
COMMENT:
Serum iron measures the amount of circulating iron that is bound to transferrin. Clinicians order this laboratory test when they are
concerned about iron deficiency, which can cause anemia and other problems.
Total iron-binding capacity The test measures the extent to which iron-binding sites in the serum can be saturated. Because the iron-
binding sites in the serum are almost entirely dependent on circulating transferrin, this is really an indirect measurement of the amount of
transferrin in the blood. Taken together with serum iron and percent transferrin saturation clinicians usually perform this test when they
are concerned about anemia, iron deficiency or iron deficiency anemia. However, because the liver produces transferrin, liver function
must be considered when performing this test. It can also be an indirect test of liver function, but is rarely used for this purpose.
*** End Of Report ***
Page 4 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Serum Reported On : 21/May/2023 12:26PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
KIDNEY FUNCTION TEST (KFT)
Urea 64.2 mg/dL 9-45
Serum, Urease, GLDH
Creatinine. 0.7 mg/dL 0.5-1.3
Serum, Jaffes
Uric Acid 3.2 mg/dl 2.3-6.0
Serum, Uricase
Sodium 139.6 mmol /L 135 - 148
Serum, Ion Selective Electrode
Potassium 4.6 mmol /L 3.7-5.5
Serum, Ion Selective Electrode
Chloride 101.3 mmol /L 98-107
Serum, Ion Selective Electrode
Calcium 8.9 mg/dl 8.4-10.3
Serum, NM BAPTA
Phosphorous Serum 3.2 mg/dl 2.6-4.5
BUN (Blood Urea Nitrogen ) 30 mg/dl 6.0-20.0
Serum, Calculated
BUN/Creatinine Ratio 42.86 Ratio 10-20
Serum, Calculated
Urea/Creatinine Ratio 91.71 Ratio
Serum, Calculated
*** End Of Report ***
Page 5 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Serum Reported On : 21/May/2023 12:26PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
LIPID PROFILE
Cholesterol 292 mg/dl <200
Serum, CHOD-PAP Enzymatic
Triglyceride 178 mg/dl <150
Serum, GPO, Colorimetric
HDL-Cholesterol 51.2 mg/dl 40-60
Serum, Homogeneous Enz.Colorimetric
LDL Cholesterol 205.2 mg/dl 0-100
Serum, Calculated
VLDL Cholesterol 35.6 mg/dl 5 - 40
Serum, Calculated
LDL / HDL Ratio 4.01 0 - 3.55
Serum, Calculated
HDL / LDL Ratio 0.25 >0.3
Serum, Calculated
Chol / HDL Ratio 5.7 0 - 4.97
Serum, Calculated
Non-HDL Cholesterol 240.8 mg/dl <160
Serum, Calculated
Lipids are a group of fats and fat-like substances that are important constituents of cells and sources of energy. The lipid profile is used as part of a cardiac risk
assessment to help determine an individual's risk of heart disease. It is recommended that healthy adults with no other risk factors for heart disease be tested with a
fasting lipid profile once every four to six years. If other risk factors are present or if previous testing revealed a high cholesterol level in the past, more frequent
testing is recommended.
TOTAL
(mg/dL) HDL (mg/dL) LDL (mg/dL) TRIGLYCERIDES (mg/dL)
CHOLESTEROL
DESIRABLE <200 LOW <40 OPTIMAL <100 NORMAL <150
BORDERLINE HIGH 200-239 HIGH >60 NEAR OPTIMAL 100-129 BORDERLINE HIGH 150-199
HIGH >240 BORDERLINE HIGH 130-159 HIGH 200-499
HIGH 160-189 VERY HIGH >500
VERY HIGH >190
*REFERENCE RANGES AS PER NCEP ATP III GUIDELINES
*** End Of Report ***
Page 6 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Serum Reported On : 21/May/2023 12:26PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
LIVER FUNCTION TEST (LFT)
Total Bilirubin 1.5 mg/dl 0.1-1.2
Serum, DCA
Conjugated Bilirubin 0.4 mg/dl 0.0-0.3
Serum, DCA
Unconjugated Bilirubin 1.1 mg/dl <1.10
Serum, Calculated
SGOT (AST) 60.8 IU/L 0 -32
Serum, Optimized UV test with IFCC
SGPT (ALT) 74.5 IU/L 0-31
Serum, Optimized UV test with IFCC
Alk.Phosphatase 62.6 IU/L 35-104
Serum, Kinetic, IFCC
T.Protein 6.8 gm/dl 6.4-8.3
Serum, Biuret
Albumin 5.2 gm/dl 3.5-5.2
Serum, Bromocresol Green
Globulin 1.6
Serum, Calculated
A/G Ratio 3.25
Serum, Calculated
SGOT/SGPT Ratio 0.82 Ratio 0-5
Serum, Calculated
COMMENTS:
A liver panel (Liver function test) or one or more of its component tests may be used to help diagnose liver disease if a
person has symptoms that indicate possible liver dysfunction. If a person has a known condition or liver disease, testing
may be performed at intervals to monitor liver status and to evaluate the effectiveness of any treatments.
*** End Of Report ***
Page 7 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Fluoride Plasma Reported On : 21/May/2023 12:43PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
SUGAR FASTING
Blood Sugar Fasting 102 mg/dl 70-110
Plasma Fluoride, Hexokinase
COMMENTS:
Fasting Blood Sugar/Glucose test. A blood sample will be taken after an overnight fast. A fasting blood sugar level less than 100 mg/dL is
normal. A fasting blood sugar level from 100 to 125 mg/dL is considered prediabetes. If it's 126 mg/dL or higher on two separate tests,
you have diabetes. (American Diabetes Association)
*** End Of Report ***
Page 8 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Serum Reported On : 21/May/2023 03:56PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
IMMUNOASSAY
Thyroid Profile-I [T3,T4,TSH]
T3 (Trilodothyronine) 110.5 ng/dl 80-220
Serum, Electro Chemi Luminescent Immuno Assay
T4 (Thyroxine) 8.3 ug/mL 5.0-12.0
Serum, Electro Chemi Luminescent Immuno Assay
TSH (Ultrasensitive) 9.519 mlU/mL 0.35-5.20
Serum, Electro Chemi Luminescent Immuno Assay
Below mentioned are the guidelines for age reference ranges for T3,T4 and TSH results:
Age Total T3 (ng/dl) Total T4 ( µg/dl) TSH (µlU/ml)
1 - 6 days 73 - 288 5.04 - 18.5 0.7 - 15.0
6 days -3 months 80 - 275 5.41 - 17.0 0.72 - 11.0
4 - 12 months 86 - 265 5.67 - 16.0 0.73 - 8.35
1 - 6 years 92 - 248 5.95 - 14.7 0.70 - 5.97
7 - 11 years 93 - 231 5.99 - 13.8 0.60 - 5.84
12 - 20 years 91 - 218 5.91 - 13.2 0.51 - 6.50
>20 years 60 - 181 4.50 - 12.6 0.13 - 6.33
TSH Level in pregnancy
First Trimester 0.10 – 2.5 µlU/ml
Second Trimester 0.20 – 3.0 µlU/ml
Third Trimester 0.30 – 3.0 µlU/ml
*** End Of Report ***
Page 9 of 10
Name : Mrs.AAMEENA Barcode No : 60008182
Age/Gender : 62 YRS/Female Reg. No : 00012305210018
Referred by : SELF Collected On : 21/May/2023 11:35 AM
Referring Centre : OPL016C-NITESH KUMAR Received On : 21/May/2023 11:42 AM
Sample Type : Serum Reported On : 21/May/2023 01:29PM
Report Status : Final
Test Name Result Unit Biological Ref.Interval
Vitamin B12 (Cynocobalamin)
Vitamin B12 Level 285.3 pg/ml 180-916
Serum, Electro Chemi Luminescent Immuno Assay
Comment:
Vitamin B12 (cobalamin) is an important water-soluble vitamin. In contrast to other water-soluble vitamins it is not excreted quickly in
the urine, but rather accumulates and is stored in the liver, kidney and other body tissues. Humans obtain Vitamin B12 exclusively from
animal dietary sources, such as meat, eggs and milk. As a result, a vitamin B12 deficiency may not manifest itself until after 5 or 6
years of a diet supplying inadequate amounts. Vitamin B12 functions as a methyl donor and works with folic acid in the synthesis of
DNA and red blood cells and is vitally important in maintaining the health of the insulation sheath (myelin sheath) that surrounds nerve
cells. Preservatives such as fluorides & ascorbic acid interfere with this assay. Excessive exposure of the specimen to light may alter
Vitamin B12 result.
Kindly correlate with clinical conditions.
Vitamin D (25-hydroxycholecalciferol)
Vitamin D, 25 Hydroxy 21.2 ng/mL 30-100
Serum, Chemi Luminescent Immuno Assay
Reference Range :
DEFICIENCY : <20 ng/ml
INSUFFICIENCY : 20-30 ng/ml
NORMAL : 30-100 ng/ml
Comments:
This test is used to determine the levels of 25-hydroxy-vitamin D and is used to determine if bone weakness, bone malformation, or abnormal metabolism of calcium is
occurring as a result of a deficiency or excess of vitamin D. Since vitamin D is a fat-soluble vitamin and is absorbed from the intestine like a fat, vitamin D is also s used
to monitor individuals with diseases that interfere with fat absorption, such as cystic fibrosis and Crohn's disease, and in patients who have had gastric bypass surgery and
may not be able to absorb enough Vitamin D. Vitamin D is also used to determine effectiveness of treatment when vitamin D, calcium, phosphorus, and/or magnesium
supplementation is prescribed. Reasons for suboptimal 25-OH-VitD levels include lack of sunshine exposure, inadequate intake; malabsorption eg, due to Celiac disease);
depressed hepatic vitamin D 25-hydroxylase activity, secondary to advanced liver disease; and enzyme-inducing drugs, in particular many antiepileptic drugs, including
phenytoin, phenobarbital, and carbamazepine, that increase 25-OH-VitD metabolism. In contrast to the high prevalence of 25-OH-VitD deficiency, hypervitaminosis D
is rare, and is only seen after prolonged exposure to extremely high doses of vitamin D. When it occurs, it can result in severe hypercalcemia and hyperphosphatemia.
Kindly correlate with clinical conditions.
*** End Of Report ***
Page 10 of
10
